Literature DB >> 9847388

New mouse model for dengue virus vaccine testing.

A J Johnson1, J T Roehrig.   

Abstract

Several dengue (DEN) virus vaccines are in development; however, the lack of a reliable small animal model in which to test them is a major obstacle. Because evidence suggests that interferon (IFN) is involved in the human anti-DEN virus response, we tested mice deficient in their IFN functions as potential models. Intraperitoneally administered mouse-adapted DEN 2 virus was uniformly lethal in AG129 mice (which lack alpha/beta IFN and gamma IFN receptor genes), regardless of age. Immunized mice were protected from virus challenge, and survival times increased following passive transfer of anti-DEN polyclonal antibody. These results demonstrate that AG129 mice are a promising small animal model for DEN virus vaccine trials.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9847388      PMCID: PMC103889     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  30 in total

1.  Synthetic peptides of the E2 glycoprotein of Venezuelan equine encephalomyelitis virus. II. Antibody to the amino terminus protects animals by limiting viral replication.

Authors:  A R Hunt; W A Short; A J Johnson; R A Bolin; J T Roehrig
Journal:  Virology       Date:  1991-11       Impact factor: 3.616

2.  Dengue virus infection of human skin fibroblasts in vitro production of IFN-beta, IL-6 and GM-CSF.

Authors:  I Kurane; J Janus; F A Ennis
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

3.  Immunization of mice with recombinant vaccinia virus expressing authentic dengue virus nonstructural protein NS1 protects against lethal dengue virus encephalitis.

Authors:  B Falgout; M Bray; J J Schlesinger; C J Lai
Journal:  J Virol       Date:  1990-09       Impact factor: 5.103

4.  Activation of T lymphocytes in dengue virus infections. High levels of soluble interleukin 2 receptor, soluble CD4, soluble CD8, interleukin 2, and interferon-gamma in sera of children with dengue.

Authors:  I Kurane; B L Innis; S Nimmannitya; A Nisalak; A Meager; J Janus; F A Ennis
Journal:  J Clin Invest       Date:  1991-11       Impact factor: 14.808

5.  High levels of interferon alpha in the sera of children with dengue virus infection.

Authors:  I Kurane; B L Innis; S Nimmannitya; A Nisalak; A Meager; F A Ennis
Journal:  Am J Trop Med Hyg       Date:  1993-02       Impact factor: 2.345

6.  Immune response in mice that lack the interferon-gamma receptor.

Authors:  S Huang; W Hendriks; A Althage; S Hemmi; H Bluethmann; R Kamijo; J Vilcek; R M Zinkernagel; M Aguet
Journal:  Science       Date:  1993-03-19       Impact factor: 47.728

7.  Human immune responses to dengue viruses.

Authors:  I Kurane; B L Innis; S Nimmannitya; A Nisalak; A L Rothman; P G Livingston; J Janus; F A Ennis
Journal:  Southeast Asian J Trop Med Public Health       Date:  1990-12       Impact factor: 0.267

8.  Dengue 2 virus envelope protein expressed by a recombinant vaccinia virus fails to protect monkeys against dengue.

Authors:  V Deubel; R M Kinney; J J Esposito; C B Cropp; A V Vorndam; T P Monath; D W Trent
Journal:  J Gen Virol       Date:  1988-08       Impact factor: 3.891

9.  Disseminated tuberculosis in interferon gamma gene-disrupted mice.

Authors:  A M Cooper; D K Dalton; T A Stewart; J P Griffin; D G Russell; I M Orme
Journal:  J Exp Med       Date:  1993-12-01       Impact factor: 14.307

10.  Response to influenza infection in mice with a targeted disruption in the interferon gamma gene.

Authors:  M B Graham; D K Dalton; D Giltinan; V L Braciale; T A Stewart; T J Braciale
Journal:  J Exp Med       Date:  1993-11-01       Impact factor: 14.307

View more
  168 in total

Review 1.  Perspectives for the treatment of infections with Flaviviridae.

Authors:  P Leyssen; E De Clercq; J Neyts
Journal:  Clin Microbiol Rev       Date:  2000-01       Impact factor: 26.132

2.  A lethal murine infection model for dengue virus 3 in AG129 mice deficient in type I and II interferon receptors leads to systemic disease.

Authors:  Vanessa V Sarathy; Mellodee White; Li Li; Summer R Gorder; Richard B Pyles; Gerald A Campbell; Gregg N Milligan; Nigel Bourne; Alan D T Barrett
Journal:  J Virol       Date:  2014-11-12       Impact factor: 5.103

3.  Dengue 2 PDK-53 virus as a chimeric carrier for tetravalent dengue vaccine development.

Authors:  Claire Y-H Huang; Siritorn Butrapet; Kiyotaka R Tsuchiya; Natth Bhamarapravati; Duane J Gubler; Richard M Kinney
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

Review 4.  Dengue epidemiology and pathogenesis: images of the future viewed through a mirror of the past.

Authors:  Rashedul Islam; Mohammed Salahuddin; Md Salahuddin Ayubi; Tahmina Hossain; Apurba Majumder; Andrew W Taylor-Robinson; Abdullah Mahmud-Al-Rafat
Journal:  Virol Sin       Date:  2015-10-20       Impact factor: 4.327

5.  Treatment with a Nucleoside Polymerase Inhibitor Reduces Shedding of Murine Norovirus in Stool to Undetectable Levels without Emergence of Drug-Resistant Variants.

Authors:  Joana Rocha-Pereira; Jana Van Dycke; Johan Neyts
Journal:  Antimicrob Agents Chemother       Date:  2015-12-28       Impact factor: 5.191

Review 6.  Recent advances in deciphering viral and host determinants of dengue virus replication and pathogenesis.

Authors:  Karen Clyde; Jennifer L Kyle; Eva Harris
Journal:  J Virol       Date:  2006-08-23       Impact factor: 5.103

7.  Induction of epitope-specific neutralizing antibodies against West Nile virus.

Authors:  Theodore Oliphant; Grant E Nybakken; S Kyle Austin; Qing Xu; Jonathan Bramson; Mark Loeb; Mark Throsby; Daved H Fremont; Theodore C Pierson; Michael S Diamond
Journal:  J Virol       Date:  2007-08-22       Impact factor: 5.103

8.  Construction and characterization of a single-cycle chimeric flavivirus vaccine candidate that protects mice against lethal challenge with dengue virus type 2.

Authors:  Ryosuke Suzuki; Evandro R Winkelmann; Peter W Mason
Journal:  J Virol       Date:  2008-12-10       Impact factor: 5.103

9.  Neuroadapted yellow fever virus 17D: genetic and biological characterization of a highly mouse-neurovirulent virus and its infectious molecular clone.

Authors:  T J Chambers; M Nickells
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

10.  A mouse-passaged dengue virus strain with reduced affinity for heparan sulfate causes severe disease in mice by establishing increased systemic viral loads.

Authors:  Tyler R Prestwood; Daniil M Prigozhin; Kristin L Sharar; Raphaël M Zellweger; Sujan Shresta
Journal:  J Virol       Date:  2008-06-18       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.